Eli Lilly's experimental drug Eloratzp showed superior A1c reduction and weight loss compared to tirzepatide 15 mg in a 48-week trial. Participants on Eloratzp achieved up to 2.9% average A1c reduction versus 2.4% for tirzepatide, and lost up to 54.1 lbs (23.3%) versus 34.4 lbs (14.8%). All combinations met primary and secondary endpoints.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
